ASCO 2022 | The current status of CAR T and CAR NK cells in multiple myeloma
Matthew Frigault, MD, Harvard Medical School, Boston, MA, comments on the progress chimeric antigen receptor T-cell (CAR-T) and chimeric antigen receptor natural killer cells (CAR NK) therapies have made in the treatment of multiple myeloma. Whilst CAR-T cells have made more progress in various trials such as the CARTITUDE-1 (NCT03548207), LEGEND-2 (NCT03090659), and KarMMa (NCT03361748) trials, CAR NK cells have only recently been investigated in phase I trials. Multiple receptors including B-cell maturation antigen (BCMA) and Fc3 are potential targets for NK cells and further research will elucidate the efficacy of NK cell therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
